ESMO Open

Papers
(The H4-Index of ESMO Open is 49. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
OP01-2 Changes in the tumor microenvironment in recurrent head and neck squamous cell carcinoma and its implication on efficacy of immune checkpoint inhibitors226
PP289 Potential anti-tumour therapy in nasopharyngeal carcinoma: MDM2 siRNA-based approaches216
PP075 Xia Yuxue decoction inhibits hepatocellular carcinoma metastasis by reducing the abundance of the tumor-resident bacterium Brachybacterium sp.175
PP153 A randomized, open-label phase ii study comparing a novel regimen of dose-dense docetaxel-cyclophosphamide alternating with epirubicin-cisplatin against anthracycline-taxane in early TNBC, strat157
PP002 Unravelling the effects of bisphenol A on colorectal cancer progression in obese Sprague-Dawley rats155
PP175 Unexpected high frequency of pathogenic germline variant (rs34804482, NM_018490.3: c.2531A>G) of the LGR4 gene in Tuvan ethnic group from West Siberia137
140P Use of chemotherapy and loco-regional therapy for stage IA triple-negative breast cancer and their association with oncologic outcomes: A cancer registry study132
35P Genomic and clinical landscape of metastatic hormone receptor-positive breast cancers carrying ESR1 alterations127
130P Progesterone receptor (P) status and survival outcomes of ER-negative breast cancer: A population-based cohort study126
137P PHANTOM: Bootstrap inference of single-cell tumour phylogenies by integrating sequencing read counts122
2O Prostate cancer BRCA mutation prediction using multiple-instance learning and histopathology122
6P An innovative evidence-based laboratory medicine (EBLM) test to help doctors in the screening of ovarian cancer110
Table of Contents99
217P Switching cyclin-dependent kinase inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/human epidermal growth factor-negative (HER2-) advanced breast cancer (ABC) who experienced95
97P Drug sensitivity prediction based on RNA expression profiling in colorectal cancer organoids91
Table of Contents91
Table of Contents90
ESMO86
107P Clinicopathologic features of breast cancer patients in a single tertiary hospital in the Philippines78
258P Real-world (rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2-negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherap74
266O Safety of assisted reproductive techniques in young BRCA carriers with a pregnancy after breast cancer: Results from an international cohort study73
115P Impact of clinical and treatment factors on trabectedin toxicity in soft tissue sarcomas69
284P Risk assessment for systemic recurrence in HER2-low breast cancer: Evaluating hormone receptors and immunohistochemical profiles69
76P Relative dose-intensity of trabectedin and outcome of advanced L-sarcomas68
143P Post-recurrence treatment in modern adjuvant or neoadjuvant soft-tissue sarcoma randomized trials: A cross-sectional study of published trials between 2015 and 202468
50P Combination of platinum-based chemotherapy with immunotherapy in treatment of extrapulmonary neuroendocrine carcinoma: A retrospective study68
22P PillPal.ai: Using artificial intelligence to improve adherence to oral chemotherapy, TKIs, and CDK4/6 Inhibitors - A pilot study from a tertiary cancer centre in India67
83P Efficacy and safety of KRAS G12C inhibitors across solid tumors: A systematic review and meta-analysis66
43eP Is age a risk factor for locally advanced cervical cancer persistence?65
Concurrent antibody–drug conjugates and radiotherapy: a new perspective on radiation necrosis in HER2-positive breast cancer brain metastases from the DESTINY-Breast03 and HER2CLIMB trials65
16eP Efficacy and safety of bevacizumab biosimilar in the treatment of brain metastases from breast cancer: A prospective, single-arm, multicentre, real-world study65
152P Pregnancy after gestational trophoblastic neoplasia: Navigating fertility post-chemotherapy65
Implementing SERENA6 in the clinic in the UAE: critical thinking of a community oncologist64
70P Development and validation of a machine learning (ML) nomogram to predict RSClin results and guide adjuvant treatment of node-negative (N0) hormone receptor-positive (HR+)/human epidermal growth f63
412TiP HEROES: De-escalation of medical therapies in HER2-positive metastatic breast cancer in long-term persistent response and minimal residual disease undetectable in circulating tumor DNA62
PP018 PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling58
Editorial Board58
68P Prognosis of ovarian cancer patients with the Mexican founder mutation (a BRCA1 long genomic rearrangement) compared with other BRCA1/2 mutations56
63P Redefining the role of CA 19-9 as a prognostic marker in epithelial ovarian cancer55
232P Real-world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom55
107P The actin cytoskeleton as a new target structure for metastasizing osteosarcoma54
57P Two cases of adult rhabdomyosarcoma of the head and neck successfully treated with pazopanib54
37P Dose transition pathways for time-to-event continual reassessment method (TITE-CRM): Will imposing a waiting time result in better performance?54
267P Ultrasound-guided injection with or without rehabilitation exercise in breast cancer survivors with subacromial-deltoid bursitis: Long-term results of a pilot randomized clinical study53
100P Combinatorial treatment strategies for overcoming the immunotherapy resistance in soft tissue sarcomas53
103P Impact of Prosigna test on treatment decision in lymph node-negative early breast cancer: A prospective multicenter study (EMIT1)53
174P Endocrine disruptors and life STILe in patients carrying BRCA pathogenic VAriants with breast and/or ovarian CAncer and women without neoplasm: The STILVARCA study52
118P Real-world treatment patterns and clinical outcomes among high risk, early stage HER2-negative breast cancer (BC) patients in Alberta, Canada52
142P The predictive value of progesterone receptor expression on pCR following neoadjuvant chemotherapy in breast cancer49
0.097671985626221